Blanca Estela Duque-Montaño

Dr. Blanca Estela Duque-Montaño


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMiriam Guadalupe Baron
Miriam Guadalupe Baron
JGJANETH GOMEZ-GARCIA
JANETH GOMEZ-GARCIA
DDDavid Durán-Martínez
David Durán-Martínez
OTOscar Torres-Angeles
Oscar Torres-Angeles
BDBlanca Estela Duque-Montaño
Blanca Estela Duque-Montaño
JRJESUS RIVERA
JESUS RIVERA
Infections caused by the protozoans Entamoeba histolytica (E. histolytica), Giardia lamblia (G. lamblia), and Trichomonas vaginalis (T. vaginalis) represent a global public health concern. Albendazole and mebendazole are drugs used to treat parasitosis resulting from protozoa. However, the low aqueous solubility of these compounds has led to the exploration of new strategies to enhance their solubility, with the formation of salts being a commonly employed strategy. The sulfonates A1, A2, and A3 of albendazole, and M1, M2, and M3 of mebendazole were synthesized, and their antiparasitic activity was determined in vitro against trophozoites of E. histolytica, G. lamblia, and T. vaginalis. Consequently, IC50 values ranged from 24.17 to 138.02 µM for the albendazole and mebendazole salts. For comparison, the IC50 values for the positive controls—albendazole, mebendazole, and metronidazole—ranged from 16.08 to 270.66 µM. Additionally, it was determined that salts A1, A3, M2, and M3 do not exhibit cytotoxic effects at concentrations of 500 µM on the VERO cell line. Taken together, these findings indicate that the formation of these new solid saline phases enhances the antiparasitic effects in vitro, which is crucial in the current search for improved, safe, and effective antiparasitic agents.

27 March 2025 in Microbiology Research
Verified
Journal Article
Open access
PDF file
MBMiriam Guadalupe Baron
Miriam Guadalupe Baron
JGJANETH GOMEZ-GARCIA
JANETH GOMEZ-GARCIA
DDDavid Durán-Martínez
David Durán-Martínez
OTOscar Torres-Angeles
Oscar Torres-Angeles
JRJESUS RIVERA
JESUS RIVERA
BDBlanca Estela Duque-Montaño
Blanca Estela Duque-Montaño
Infections from the protozoa Entamoeba histolytica (E. histolytica), Giardia lamblia (G. lamblia), and Trichomonas vaginalis (T. vaginalis) pose a public health issue, with albendazole and mebendazole serving as the second-line medications for treating these parasitic infections. However, the low aqueous solubility of these compounds has led to the exploration of new strategies to enhance their solubility, with the formation of salts being a commonly employed strategy. The sulfonates A1, A2, and A3 of albendazole, along with M1, M2, and M3 of mebendazole, were synthesized. The antiparasitic activity in vitro was assessed against the trophozoites of E. histolytica, G. lamblia, and T. vaginalis. The salts A2, A3, M2, and M3 demonstrated a greater antiparasitic effect (IC50 37.95–125.53 µM) compared to the positive controls albendazole and mebendazole. The salts A1, A3, M2, and M3 do not exhibit cytotoxic effects at concentrations of 500 µM on the Vero cell line. Taken together, these findings indicate that the formation of these new solid saline phases enhances the antiparasitic effects in vitro, which is crucial in the current search for improved, safe, and effective antiparasitic agents.